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Transformation is the evolution of an indolent lymphoma/leukemia to an aggressive
lymphoma, typically harboring a very poor prognosis. This phenomenon is well described
in humans, but underestimated in dogs although recognized as a possible evolution
of indolent lymphomas/leukemias. In canine chronic leukemias, blast crisis (mainly in
myeloid) and Richter syndrome (transformation into a high grade lymphoma) (mainly in
B-cell lymphocytic leukemia) have been reported. Transformation is a possible event
also in canine low grade lymphomas, although rare. The increased knowledge has also
generated new questions and posed challenges that need to be addressed to improve
outcome, including the recognition of the clinical characteristics at diagnosis associated
with a higher risk of transformation in an attempt of anticipating the typical evolution.
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Introduction
Transformation of an indolent low grade lymphoma into amore aggressive histotype is a well-known
process in human hemato-oncology, generally linked to unfavorable prognosis and poor outcome.
Histological transformation of follicular lymphoma (FL) into more aggressive lymphoma subtypes
is a pivotal event in the natural history of patients, representing one of the major challenges in the
management of patients with FL. Chronic lymphocytic leukemia (CLL) are commonly reported to
progress into aggressive high grade lymphoma (Richter syndrome, RS) or acute leukemia (blast
crisis). Transformation has been reported also in other subtypes of low grade lymphomas, either
B-cell (marginal zone lymphoma – MZL, mantle cell lymphoma – MCL, mucosa-associated lym-
phoid tissue lymphoma –MALT) or T-cell in origin (mycosis fungoides –MF), and generally implies
the histological effacement of the nodal architecture and/or the increase in the proportion of large
cells (1), together with the onset of clinical signs.
Even though the term “transformation” implies the direct evolution of neoplastic cells into
more aggressive ones this might not be the case and efforts have been made to determine the
origin of transformed neoplastic cells (arising from the same clones or from different ones) as
well as to identify possible pathogenetic mechanisms driving transformation. As a matter of fact,
transformation implies the shift to a more aggressive clinical behavior and justifies the need of an
aggressive therapeutic approach.
In veterinary oncology, the issue of transformation of lymphoma/leukemia into more aggressive
forms is debated but anecdotic.
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Aim of the present article is to review the veterinary literature
and to describe the authors’ experience.
Basis of Transformation
Different factors, including genetic modifications, epigenetic
transformation, and microenvironment, may contribute to repro-
graming the original neoplastic cells and lead to transformation
into a more aggressive histological pattern.
During transformation, two different scenarios may occur: (1)
a specific neoplastic clone undergoes multiple and sequential
mutations, leading to less differentiated neoplastic cells with a
more aggressive behavior or (2) different clones from the original
neoplastic ones desegregate and proliferate, thereby replacing the
previous tumor (2).
Both the scenarios may be alternatively possible. In most cases
of RS, neoplastic cells are clonally related to the original CLL,
whereas in a minority of cases (<20%), new clones develop as a
“de novo” neoplasm (3). However, even if clonally related, a direct
evolution of indolent into the new aggressive neoplastic cells is
not universally accepted. For instance, there is some evidence that
the transformed tumor may arise from common precursor cells
rather than directly evolving from the primary clone, as described
for FL (2).
Hematopoietic Neoplasm Undergoing
Transformation
Chronic Myeloid Leukemia
If untreated, human chronic myeloid leukemia (hCML) may
typically transform into aggressive leukemia. hCML may evolve
to an accelerated phase characterized by increased percentages
of abnormal blast cells (10–19% of total nucleated cells in the
bone marrow), unresponsive thrombocytopenia/thrombocytosis,
basophilia, leukocytosis, unresponsive anemia, and splenomegaly
(4). The final evolution of this accelerated phase is the blast crisis,
in which the blast percentage in the bone marrow exceeds 20%,
and clinical symptoms become apparent. Most hCML in blast
crisis resemble acute myeloid leukemia (AML), whereas approxi-
mately one-third of them mimic acute lymphoid leukemia (ALL)
(5). Based on the above, it may be speculated that transformed
neoplastic cells likely derive from a common undifferentiated
precursor rather than directly from hCML neoplastic cells. The
immunophenotype of transformed cells reveals an undifferen-
tiated pattern, including positivity to CD34 and CD7 in many
cases (6). Chromosomal and molecular secondary aberrancies, in
addition to the classic Philadelphia chromosomewith t(9:22), gen-
erally occur during transformation (7). These changes may reflect
the accumulation of genetic abnormalities of neoplastic cells in
addition to the primary BCR–ABL translocation, thus preventing
cell differentiation and leading to uncontrolled proliferation (4).
Chronic myelomonocytic leukemia (CMML) is a myeloprolif-
erative/myelodysplastic neoplasm that naturally evolves to AML
in 15–30% of cases and only rarely to ALL. According to the
percentage of blast cells, CMML are subdivided into two groups
(type 1 and type 2 CMML), with type 2 roughly corresponding to
the accelerated phase of CML (8).
Canine Chronic Myeloid Leukemia
To the authors’ knowledge, large series on transformation of
canine CML or CMML have not been described. However, some
isolated cases of blast crisis have been reported (9), but it is
generally considered as rare in dogs (10). This is probably due to
the rarity of myeloproliferative neoplasms in dogs and to the dif-
ficulties in distinguishing between blast crisis and primary AML,
if clinical and laboratory history is inadequate. However, in the
authors’ experience, accelerated phase and blast crisis in dogs with
CML and CMML are not exceptional findings (Figure 1). The
percentage of canine myeloproliferative neoplasms undergoing
blast transformation may be difficult to estimate, also because
CML and CMML may arise asymptomatically, and clinical signs
may become evident during transformation.
Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia is a common hematological neo-
plasm both in humans and dogs. Human CLL (hCLL) have a
characteristic B CD5+ phenotype. Three main different types of
evolution of CLL have been reported (3): (1) RS, (2) prolympho-
cytic leukemia, and (3) blast crisis.
Richter syndrome refers to the rapid development of an aggres-
sive lymphoma in patients with CLL, occurring in 2–20% of
hCLL. Most frequently (90% of cases), B-CLL transforms into dif-
fuse large B-cell lymphoma (DLBCL), rarely (10%) into Hodgkin
lymphoma (11).
In the pathogenesis of RS, the large cells diffusely infiltrat-
ing the lymph node structure may arise from a transformation
of the original CLL clone (approximately 80% of cases), due to
the accumulation of genetic and/or epigenetic lesions. In the
remaining 20% of cases, RS represents a “de novo” lymphoma
and the pathogenesis is likely related to host genetic background
or microenvironmental dysfunction, enhancing the probability of
DLBCL (12). Some molecular markers have been associated with
RS transformation. They include clinical (advanced Rai stage),
immunophenotypic (ZAP-70, CD38, CD49d), genetic (del-17p,
del-11q) characteristics at the time of CLL diagnosis, and single
nucleotide somatic mutations, including TP53 disruption, c-myc
activation, CDKN2A loss, and NOTCH1 mutations (3).
Prolymphocytic leukemia is uncommon and is characterized
by increased cells at their intermediate development stage, mas-
sive splenomegaly, and onset of clinical signs. Prolymphocytes
are medium sized cells with visible nucleoli and decondensed
chromatin.
Finally, blast crisis may occur as described for CML cases, but
it is usually rare.
Canine Chronic Lymphocytic Leukemia
In contrast with human counterpart, about two-thirds of canine
CLL are of T phenotype. Data regarding evolution and possible
transformation of canine chronic lymphocytic leukemia (cCLL) in
more aggressive neoplasms are fragmentary. RS has been reported
in 2 cases out of a series of 22 cCLL (13). Recently, we reported
8 cases of RS (6 having B-cell phenotype and 2 having T-cell
phenotype) in a cohort of 153 cCLL cases (93 T-CLL, 55 B-CLL, 5
atypical CLL) (14). RS in B-cCLL showed a prevalence similar to
that described in hCLL (10.9%). During Richter transformation,
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FIGURE 1 | Peripheral blood (A) and bone marrow (B) from a dog with Chronic myeloid leukemia in blast transformation. A high percentage of blast cells
(arrows) are found mainly in the bone marrow aspirate. May–Grünwald–Giemsa stain, 40.
dogs exhibited a decrease of lymphocyte counts, often associated
with anemia and thrombocytopenia, lymphadenomegaly with
cytological and histological features of DLBCL, and onset of
clinical signs. Outcome was poor, with a median survival time
of 41 days. In agreement with the human literature, RS is also a
possible evolution of cCLL, moreover in the case of B phenotype.
However, clonality has been evaluated in two cases only, and it was
not possible to determine if the described cases were all clonally
related or represented a “de novo” tumor.
Regarding the other types of transformation, Takahashi et al.
(15) reported blast crisis in one dogwith T-LGLCLLwith a shift of
immunophenotype from CD3+CD8+ CLL to CD3 CD8  ALL,
coupled with anemia and thrombocytopenia. Once again, it was
impossible to determine if the two diseases were clonally related.
Other cases of blast crises have been reported in different case
series (9). Burnett et al. (16) reported a case of B-cCLL evolving
into a clonally related multiple myeloma following chemotherapy.
Transformation of cCLL into prolymphocytic leukemia is
poorly reported but, to the authors’ experience, this evolution is
likely underestimated also due to the lack of specific markers.
Evolution to prolymphocytic leukemia should be suspected if the
morphological evaluation of the blood smear reveals medium
sized nucleolated cells, in addition to an aggressive clinical course.
Follicular Lymphoma
Follicular lymphoma is the most frequent human lymphoma
and the transformation to a high grade lymphoma is a well-
known evolution, ranging from 10 to 60% of cases (1). Typically,
FC transforms into DLBCL, whereas transformation into Burkitt
lymphoma, ALL, or lymphoblastic lymphoma seems to occur
at a lesser incidence. An increase in the proportion of centrob-
lasts and the parallel effacement of the follicular architecture
are pivotal events, and transformed DLBCL frequently maintains
the germinal center (GC) pattern expressing BCL6 and CD10
and the genetic features characteristic of FL, such as t(14:18).
Recent studies suggested that transformation of FL into DLBCL
is frequently a non-linear event, with transformed cells deriving
more frequently from a common progenitor harboring driver
mutations rather than directly from the predominant clone of FL
(17). Several events may foster transformation, including genetic
alterations (MYC, p53, p16, BCL6, BCL2), epigenetic factors, and
themicroenvironment (follicular dendritic cells, microvessel) and
intra follicular non-neoplastic lymphoid cells (CD4+ and Tregs).
From a clinical point of view, the rise of B symptoms (fever,
night sweats, and weight loss), nodal growth, hypercalcemia, and
increased LDH level are common features. Most studies report a
poor prognosis, with survival after transformation ranging from
months to few years.
Canine Follicular Lymphoma
In contrast with humans, FLs are rare in dogs, representing
no more than 1% of cases (18). To the authors’ knowledge,
transformation of canine follicular lymphoma (cFL) in DLBCL
has not been directly reported. This may be due to the poor
propensity to have a histopathological diagnosis at presentation
and moreover at relapse, rather than to a true low incidence.
Between 2011 and 2015, at one of the authors’ institutions (LM),
13 dogs with cFL were diagnosed and treated. Data concerning
signalment, symptoms, initial staging work-up, treatment, and
follow-up were known in all cases. Histological diagnosis was
obtained in all cases. First-line therapy for these 13 dogs was
administered according to protocols used at that time and con-
sisted of dose-intense chemotherapy. Dogs were fully restaged at
progression, and all of them underwent lymphadenectomy and
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FIGURE 2 | Histopathology of lymph nodes from the same dog at presentation (A) and after transformation (B). A follicular lymphoma was diagnosed at
presentation transforming into diffuse large B-cell lymphoma after therapy and recurrence. Hematoxylin–Eosin stain, 10.
histopathological evaluation. The diagnosis of transformationwas
always based on histology and was defined by the histological fea-
tures of DLBCL. Transformation was documented in 2 (15.4%) of
13 dogs at their first recurrence (Figure 2). Both dogs were treated
with rescue chemotherapy and eventually died with progression
after few months.
In a previous study by the group, Array Comparative Genomic
Hybridization in canine DLBCL was carried out at diagnosis and
at relapse to compare the profiles (19). Overall, relapsed DLBCLs
showed a lower number of chromosomal rearrangements when
compared with the corresponding primary DLBCLs. Few dogs
had the same profile, suggesting a linear clonal evolution; how-
ever, the majority of dogs showed a more complicated profile in
terms of aberrations, and new rearrangements were also detected.
Different scenarios can explain this molecular transformation
at relapse. Chemotherapy alters the growth conditions of the
neoplastic cells, thereby having a strong impact on the selection
process of the resistant clones. If neoplastic cells dominating
at diagnosis are sensitive to therapy, minor clones with intrin-
sic resistance may be secondarily generated by the tumor, and
expandmore efficiently once the competing clones are eliminated
by the treatment. In dogs with the same pattern of chromoso-
mal rearrangements, a reduced effect of the therapeutic protocol
was confirmed. Our analysis identified relevant genes that may
be also novel targets of chromosomal aberrations in relapsed
DLBCL.
Other Low Grade B-Cell Lymphomas
Although less frequently, transformation has been occasionally
reported in other low grade B-cell lymphomas. Xing et al. (20)
recently reported a transformation rate of 18% in splenic MZL.
Meyer et al. (21) identified transformation, usually to DLBCL, as
an independent unfavorable prognostic factor in MZL regardless
of the origin (nodal, splenic, or MALT) and of subtype. The fre-
quency of transformation ofMZL is about 2.4% and is not far from
that reported in FL (about 3%). Different mutations have been
hypothesized to be associated with high grade transformation, but
no definitive predictors of transformation have been recognized.
Canine MZLs are quite frequent in the spleen, mainly with a
nodal architecture, often showing an indolent behavior, whereas
nodal subtypes tend to exhibit a more aggressive behavior with a
tendency to diffuse pattern and generalization (22). From a histo-
logical perspective, nodal MZL originates in a follicular fashion,
but tends to progress in a diffuse fashion involving and compress-
ing the entire lymph node. Valli et al. (22) have described this
phenomenon as MZL late stage. Over 4 years, 26 dogs with nodal
MZL were fully staged and treated at the authors’ institutions.
Among them, one (3.8%) underwent transformation intoDLBCL,
which was histologically confirmed. Despite rescue treatment, the
dog progressed and eventually died.
Transformation of lymphoplasmacytic lymphoma (23) has
been rarely reported. MCL is generally aggressive, although rarely
a more indolent behavior is reported. Transformation of MCL to
aggressive pleomorphicMCL (24) or lymphoblastic leukemia (25)
has been reported in humans.
In dogs,MCL is extremely rare (<2%) (18), andmainly confined
to the spleen. Data on transformation are currently lacking.
According to the authors’ experience, canine B-cell small lym-
phocytic lymphoma (cB-SLL) can also undergo transformation.
Among six cB-SLLdiagnosed over 4 years, two (33.3%) underwent
transformation into DLBCL, thereby representing the lymphoma
histotype with the highest risk of histological transformation.
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T Cell Lymphomas
T-Cell Lymphomas
Although transformation has generally been focused in low grade
B-cell lymphomas, several cases of transformed T-cell lymphomas
are documented in human medicine.
Transformation of nodal T-cell lymphoma is rarely reported,
since aggressive high grade lymphoma is highly prevalent in nodal
forms.
In dogs, indolent T-cell lymphomas are not rare,mainly showing
a T-zone derivation (TZL) (18, 26, 27). This subtype is char-
acterized by long survival and indolent behavior. We recently
described 51 TZLs (28). In those cases for which a complete
follow-up was available, an indolent behavior was confirmed, and
transformation never occurred. Interestingly, TZLs maintained a
peculiar nodular architecture also in dogs having a clinical history
of continuous relapse pattern and severe peripheral blood and
bone marrow infiltration. A diffuse transformation seems not
typical of this tumor.
On the other side, being one of the most diffuse indolent T-
cell lymphoma in humans, MF (cutaneous epitheliotropic lym-
phoma) is frequently reported to progress and transform to
more aggressive, large cells, and high grade neoplasms (29–31).
Some prognostic indices, including immunophenotype, follicu-
lotropism, and the extent of skin lesions, have been identified
(30). Transformation has been reported to occur in 20–50% of
patients with advanced MF (32) and is generally linked to a poor
prognosis.
Canine MF generally harbors a poor prognosis in contrast
with the human counterpart (32). Studies with large caseloads are
lacking, but in none of the reported case series transformation to
aggressive large cell lymphoma has been reported (33–35).
Conclusion
Transformation of indolent lymphomas into more aggressive his-
tological subtypes is still widely unexplored in veterinary oncol-
ogy, although some evidences exist as a support. Oncologists and
pathologists should carefully consider transformation as a pos-
sible scenario, mainly in the case of B-cell lymphoma/leukemia,
similarly towhat reported in humanmedicine.Nevertheless, some
differences exist, being mainly related to the different incidence
of some lymphoma subtypes. Efforts should be made to collect
an adequate caseload of canine indolent lymphomas in order
to define prevalence of transformation and to identify possible
biomarkers useful for understanding pathogenesis and stratify
patients in risk groups. Based on our personal experience and
in agreement with the human literature, the grave prognostic
significance of transformation is clear, as dogs in which it occurs
had a very poor outlook, rendering transformation a therapeutic
challenge.
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